FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221027008> ?p ?o ?g. }

• W4221027008 abstract "Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the efficacy and safety of MSCs combined with basiliximab and calcineurin inhibitor as second-line therapy for SR aGVHD.A randomized phase 3 trial involved 203 SR aGVHD patients at nine centers in China (September 2014-March 2019). Participants were randomized at a 1:1 ratio to receive second-line therapy with (n = 101) or without (n = 102) MSCs. The primary endpoint was the overall response (OR) at day 28. Secondary and safety endpoints included durable OR at day 56, failure-free survival, overall survival (OS), chronic GVHD (cGVHD), infection, hematological toxicity and relapse.Of 203 patients, 198 (97.5%; mean age, 30.1 years; 40.4% women) completed the study. The OR at day 28 was higher in the MSC group than the control group (82.8% [82 patients] vs. 70.7% [70]; odds ratio, 2.00; 95% confidence interval [CI], 1.01-3.94; P = 0.043). The durable OR at day 56 was also higher in the MSC group (78.8% [78 patients] vs. 64.6% [64]; odds ratio, 2.02; 95% CI, 1.08-3.83; P = 0.027). The median failure-free survival was longer in the MSC group compared with control (11.3 months vs. 6.0 months; hazard ratio (HR) 0.68; 95% CI, 0.48-0.95, P = 0.024). The 2-year cumulative incidence of cGVHD was 39.5% (95% CI, 29.3-49.4%) and 62.7% (51.4-72.1%) in the MSC and control groups (HR 0.55, 95% CI, 0.36-0.84; P = 0.005). Within 180 days after study treatments, the most common grade 3 and 4 adverse events were infections (65 [65.7%] in the MSC group vs. 78 [78.8%] in the control group) and hematological toxicity (37 [37.4%] vs. 53 [53.5%]). The 3-year cumulative incidence of tumor relapse was 10.1% (95% CI, 5.2-17.1) and 13.5% (7.5-21.2%) in the MSC and control groups, respectively (HR 0.75, 95% CI, 0.34-1.67, P = 0.610).MSCs plus second-line treatments increase the efficacy of SR aGVHD, decrease drug toxicity of second-line drugs and cGVHD without increasing relapse, and are well-tolerated. MSCs could be recommended as a second-line treatment option for aGVHD patients. Trial registration clinicaltrials.gov identifier: NCT02241018. Registration date: September 16, 2014, https://clinicaltrials.gov/ct2/show/NCT02241018 ." @default.
• W4221027008 created "2022-04-03" @default.
• W4221027008 creator A5000828146 @default.
• W4221027008 creator A5006651636 @default.
• W4221027008 creator A5022759903 @default.
• W4221027008 creator A5029592269 @default.
• W4221027008 creator A5031468074 @default.
• W4221027008 creator A5032457247 @default.
• W4221027008 creator A5036634103 @default.
• W4221027008 creator A5041130348 @default.
• W4221027008 creator A5041183580 @default.
• W4221027008 creator A5042449700 @default.
• W4221027008 creator A5045238753 @default.
• W4221027008 creator A5046665506 @default.
• W4221027008 creator A5046892926 @default.
• W4221027008 creator A5050562004 @default.
• W4221027008 creator A5051439492 @default.
• W4221027008 creator A5053447705 @default.
• W4221027008 creator A5070538645 @default.
• W4221027008 creator A5071212122 @default.
• W4221027008 creator A5073479438 @default.
• W4221027008 creator A5079594267 @default.
• W4221027008 date "2022-03-07" @default.
• W4221027008 modified "2023-10-16" @default.
• W4221027008 title "Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial" @default.
• W4221027008 cites W1676794103 @default.
• W4221027008 cites W1944600343 @default.
• W4221027008 cites W1979043688 @default.
• W4221027008 cites W1982408656 @default.
• W4221027008 cites W1983493560 @default.
• W4221027008 cites W1988489929 @default.
• W4221027008 cites W1988753148 @default.
• W4221027008 cites W1999834650 @default.
• W4221027008 cites W2012132345 @default.
• W4221027008 cites W2012302358 @default.
• W4221027008 cites W2013107151 @default.
• W4221027008 cites W2015050458 @default.
• W4221027008 cites W2020828534 @default.
• W4221027008 cites W2022676366 @default.
• W4221027008 cites W2024088021 @default.
• W4221027008 cites W2038799368 @default.
• W4221027008 cites W2058473775 @default.
• W4221027008 cites W2060391615 @default.
• W4221027008 cites W2070842082 @default.
• W4221027008 cites W2083086726 @default.
• W4221027008 cites W2092929403 @default.
• W4221027008 cites W2095610616 @default.
• W4221027008 cites W2113148633 @default.
• W4221027008 cites W2123368042 @default.
• W4221027008 cites W2138946470 @default.
• W4221027008 cites W2143258371 @default.
• W4221027008 cites W2155044423 @default.
• W4221027008 cites W2158048826 @default.
• W4221027008 cites W2160666689 @default.
• W4221027008 cites W2162729702 @default.
• W4221027008 cites W2166672922 @default.
• W4221027008 cites W2187102810 @default.
• W4221027008 cites W2379365975 @default.
• W4221027008 cites W2400770646 @default.
• W4221027008 cites W2460851798 @default.
• W4221027008 cites W2465027035 @default.
• W4221027008 cites W2479125356 @default.
• W4221027008 cites W2578543203 @default.
• W4221027008 cites W2596992695 @default.
• W4221027008 cites W2754160328 @default.
• W4221027008 cites W2769990542 @default.
• W4221027008 cites W2805930313 @default.
• W4221027008 cites W2897264084 @default.
• W4221027008 cites W2902737298 @default.
• W4221027008 cites W2964387776 @default.
• W4221027008 cites W2972161970 @default.
• W4221027008 cites W2982096484 @default.
• W4221027008 cites W2986425776 @default.
• W4221027008 cites W2993278748 @default.
• W4221027008 cites W3003983037 @default.
• W4221027008 cites W3004031232 @default.
• W4221027008 cites W3017197871 @default.
• W4221027008 cites W3017383148 @default.
• W4221027008 cites W3038797253 @default.
• W4221027008 cites W3047808971 @default.
• W4221027008 cites W3127853020 @default.
• W4221027008 cites W3147565893 @default.
• W4221027008 cites W3164618377 @default.
• W4221027008 cites W3172965236 @default.
• W4221027008 cites W3200019819 @default.
• W4221027008 cites W3208309566 @default.
• W4221027008 cites W3211554128 @default.
• W4221027008 doi "https://doi.org/10.1186/s13045-022-01240-4" @default.
• W4221027008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35255929" @default.
• W4221027008 hasPublicationYear "2022" @default.
• W4221027008 type Work @default.
• W4221027008 citedByCount "19" @default.
• W4221027008 countsByYear W42210270082022 @default.
• W4221027008 countsByYear W42210270082023 @default.
• W4221027008 crossrefType "journal-article" @default.
• W4221027008 hasAuthorship W4221027008A5000828146 @default.
• W4221027008 hasAuthorship W4221027008A5006651636 @default.
• W4221027008 hasAuthorship W4221027008A5022759903 @default.
• W4221027008 hasAuthorship W4221027008A5029592269 @default.
• W4221027008 hasAuthorship W4221027008A5031468074 @default.

• next